Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical will cancel 4,763,348 of its common treasury shares, representing 6.34% of its issued shares before cancellation, with a scheduled effective date of May 12, 2026. The move, which will reduce the total number of issued shares to 70,401,547 and is contingent on shareholder approval of a planned share consolidation, signals active capital management that may affect share value and ownership structure for investors.
The cancellation covers all treasury shares held as of February 28, 2026, aligning the company’s balance sheet with its broader restructuring of share units and articles of incorporation. By tightening the share float while proceeding with a consolidation, Hisamitsu is pursuing a leaner equity base that could enhance capital efficiency and potentially influence its market positioning in the pharmaceutical sector.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen7130.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based drugmaker best known for its pharmaceutical products, including topical treatments, and operates in the broader healthcare and medical industry. The company’s shares are publicly traded, and it actively manages its capital structure and shareholder base through measures such as share consolidations and treasury share cancellations.
Average Trading Volume: 574,079
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen440.7B
For an in-depth examination of 4530 stock, go to TipRanks’ Overview page.